Novo Nordisk is the only company in the USA with FDA-approved products (Ozempic, Wegovy, and Rybelsus) containing Semaglutide, a GLP-1 receptor agonist.
Increasing demand that has led to shortages and high cost for injectable anti-obesity drugs have driven patients to seek alternatives resulting in the growth of compounding pharmacies selling bespoke versions as a substitute for weight loss drugs.
The FDA permits compounding of Semaglutide due to shortages or when commercially available medication is not suitable for a particular patient but only if compounding pharmacies and outsourcing facilities are regulated by Section 503A and Section 503B of the Federal Food, Drug, and Cosmetic Act.
In this article, we will focus on the pros and cons of using Compounded Semaglutide and its branded counterpart Ozempic.